Compare DexCom, Inc. (DXCM) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Sibanye Stillwater Ltd — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Sibanye Stillwater Ltd trades at $10.64 (market cap $7.54B). The key difference: DexCom, Inc. is far larger — about 4.5× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 2.93% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SBSW | |
|---|---|---|
Market Cap | $33.79B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $21.12 |
52-Week Low | $54.84 | $7.27 |
Enterprise Value | $33.24B | $9.19B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Sibanye Stillwater (SBSW) trades at $10.77, up 0.94% with a bullish technical signal. Despite negative profitability metrics, the stock shows attractive valuation with P/E of 4.76 and P/S of 0.94. Recent earnings misses contrast with improved cash flow projections for 2025. Analyst consensus is mixed with 42.9% buy ratings and $14.25 price target, suggesting 32% upside potential.
The stock presents a value opportunity with deep undervaluation but carries significant execution risk. Key catalysts include debt reduction initiatives and commodity price recovery, while persistent negative margins and volatile earnings remain concerns. Institutional sentiment leans cautiously optimistic given the substantial discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
